The study employs a double-blind, randomized clinical trial design with 50 patients diagnosed with subdeltoid bursitis. Participants are divided into two groups: ultra-high-molecular-weight hyaluronic acid or high-molecular-weight hyaluronic acid injection. All injections are guided by ultrasound. Assessments are conducted before treatment and at 1 week, 1 month, and 3 months post-treatment.
Inclusion Criteria:
Unilateral shoulder pain within the past 3 months
Pain during joint movements such as abduction or internal rotation
At least one positive result from the following tests: Painful arc, Neer test, or Hawkins test
No shoulder injections received in the past 3 months
Willingness to receive injection treatment and undergo follow-up assessments
Avoid use of anti-inflammatory painkillers during the study period as much as possible; if intolerable pain occurs, acetaminophen (provided by the researcher) will be used to relieve symptoms
Exclusion Criteria:
Presence of infectious disease, inflammation, rheumatoid arthritis, or fracture
History of malignancy
Previous shoulder surgery
Sensory deficits
Total tendon rupture of the rotator cuff or biceps tendon
Neurological disorders causing hand weakness or affecting shoulder mobility (e.g., stroke, Parkinson's disease, brachial plexus injury, peripheral neuropathy) Cognitive impairment preventing completion of questionnaires
Cervical radiculopathy
Diagnosed frozen shoulder (adhesive capsulitis)
Psychiatric disorders
Breastfeeding or pregnant women
Received shoulder injection within the past 3 months, including corticosteroids, hyaluronic acid, Platelet-rich plasma, or any prolotherapy solution
rulanhsieh@gmail.comTelephone: 886 + 2-28332211 Ex